文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

CRISPR引导的胞苷脱氨酶实现治疗性外显子跳跃并在体内挽救营养不良性心肌病

Therapeutic Exon Skipping Through a CRISPR-Guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy in Vivo.
PubMed 文献 · Circulation · 2021-10-26

研究利用携带4bp缺失的DmdE4*小鼠模型模拟DMD,通过AAV9递送CRISPR/Cas9-AID(eTAM)进行胞苷碱基编辑以诱导外显子跳跃。单次 neonatal 给药实现>50%靶向外显子跳跃、心脏中高达90%抗肌萎缩蛋白恢复,改善心脏和骨骼肌功能并延长寿命,且效果持续至少1年。

要点

  • DmdE4*小鼠再现DMD心肌病表型,寿命缩短约50%。
  • AAV9-eTAM单次给药实现>50%外显子跳跃和心脏90%抗肌萎缩蛋白恢复。
  • 治疗可长期改善心脏与骨骼肌功能并延长寿命至少1年。

核心结论

  • 通过增强型TAM(eTAM)实施外显子跳跃在体内具有可行性和疗效,可挽救营养不良性心肌病。

研究设计与样本

  • 研究采用新型DmdE4*小鼠模型(Dmd基因外显子4引入4bp缺失),通过AAV9递送CRISPR/Cas9-AID(eTAM)与AAV9-sgRNA至新生小鼠,并在治疗后2或12个月分析。

主要发现

  • DmdE4*小鼠重现人类DMD多个方面,包括寿命缩短约50%、进行性心肌病、后凸畸形、肌力显著丧失和肌细胞变性。
  • 单次AAV9-eTAM给药在Dmd转录本中实现>50%靶向外显子跳跃,并在心脏中恢复高达90%的抗肌萎缩蛋白。
  • 治疗阻止早期心室重构,改善心脏和骨骼肌功能,延长DmdE4*小鼠寿命。
  • 尽管AAV载体和碱基编辑器表达逐渐下降,抗肌萎缩蛋白恢复和肌肉营养不良病理生理挽救持续至少1年。

临床怎么用

  • 该策略为DMD相关心肌病提供了潜在的一次性基因治疗方向,需进一步临床前和临床验证。

局限性

  • 研究仅在小鼠模型中进行,尚未在人体验证;AAV载体和碱基编辑器表达随时间下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Loss of dystrophin protein causes Duchenne muscular dystrophy (DMD), characterized by progressive degeneration of cardiac and skeletal muscles, and mortality in adolescence or young adulthood. Although cardiac failure has risen as the leading cause of mortality in patients with DMD, effective therapeutic interventions remain underdeveloped, in part, because of the lack of a suitable preclinical model. METHODS: We analyzed a novel murine model of DMD created by introducing a 4-bp deletion into exon 4, one of the exons encoding the actin-binding domain 1 of dystrophin (referred to as DmdE4* mice). Echocardiography, microcomputed tomography, muscle force measurement, and histological analysis were performed to determine cardiac and skeletal muscle defects in these mice. Using this model, we examined the feasibility of using a cytidine base editor to install exon skipping and rescue dystrophic cardiomyopathy in vivo. AAV9-based CRISPR/Cas9-AID (eTAM) together with AAV9-sgRNA was injected into neonatal DmdE4* mice, which were analyzed 2 or 12 months after treatment to evaluate the extent of exon skipping, dystrophin restoration, and phenotypic improvements of cardiac and skeletal muscles. RESULTS: DmdE4* mice recapitulated many aspects of human DMD, including shortened life span (by ≈50%), progressive cardiomyopathy, kyphosis, profound loss of muscle strength, and myocyte degeneration. A single-dose administration of AAV9-eTAM instituted >50% targeted exon skipping in the Dmd transcripts and restored up to 90% dystrophin in the heart. As a result, early ventricular remodeling was prevented and cardiac and skeletal muscle functions were improved, leading to an increased life span of the DmdE4* mice. Despite gradual decline of AAV vector and base editor expression, dystrophin restoration and pathophysiological rescue of muscular dystrophy were long lasted for at least 1 year. CONCLUSIONS: Our study demonstrates the feasibility and efficacy to institute exon skipping through an enhanced TAM (eTAM) for therapeutic application(s).

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Li J, Wang K, Zhang Y, et al. Therapeutic Exon Skipping Through a CRISPR-Guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy in Vivo. Circulation. 2021. PMID: 34698513. doi:10.1161/CIRCULATIONAHA.121.054628

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。